11 September

S01: Human biomonitoring – a view to the future based on current achievements

人類生物監(jiān)測--基于現(xiàn)有進(jìn)展的未來展望

S03: Current and future perspectives on the extended one-generation reproductive toxicity study (EOGRTS)

延長一代生殖毒性檢測（EOGRTS）的當(dāng)前情況與未來展望

S05: Consideration of the endogenous exposome in risk assessment

風(fēng)險評估中對內(nèi)源性暴露體因素的考慮

S07: Involvement of mitochondria in adverse drug reactions

線粒體參與藥物不良反應(yīng)

S09: Current use of NAMS/alternatives in DART testing

目前在 DART 測試中使用的NAMS/替代方法

S11: Contact allergen potency: the missing piece in the huge puzzle of alternative methods

接觸過敏原效力：替代方法的巨大難題中缺失的一環(huán)

S12: Finding synergies for 3Rs – toxicokinetics, physiologically-based kinetic (PBK) models and read-across

尋找 3R 的協(xié)同作用--毒代動力學(xué)、基于生理學(xué)的動力學(xué) (PBK) 模型和讀數(shù)交叉

12 September

S13: Acceptance and use of in vitro methods: a perspective from various chemical sectors

體外方法的應(yīng)用：來自不同化學(xué)領(lǐng)域的視角

S14: NAM mechanistic information for the risk assessment of chemical mixtures

用于化學(xué)混合物風(fēng)險評估的NAM機(jī)理信息

S15: Next generation risk assessment of food chemicals, environmental contaminants and pharmaceuticals using open-source modelling platforms: perspectives from regulatory agencies, academia and industry

利用開源建模平臺對食品化學(xué)品、環(huán)境污染物和藥品進(jìn)行下一代風(fēng)險評估：來自監(jiān)管機(jī)構(gòu)、學(xué)術(shù)界和工業(yè)界的觀點

S16: Organ-on-a-chip and the developing role in early drug development

器官芯片和在早期藥物開發(fā)中發(fā)揮的作用

S17: Critical organs and exposure windows for developmental immunotoxicity assessment

發(fā)育期免疫毒性評估的關(guān)鍵器官和暴露窗口

S20: Are diseases and conditions related to hormone imbalance really increasing?

與荷爾蒙失調(diào)有關(guān)的疾病和病癥真的在增加嗎？

S21: Environmental chemical mixtures and cancer hallmarks – new developments and open questions

環(huán)境化學(xué)混合物和癌癥標(biāo)志--新進(jìn)展和未決問題

S22: Role of immunity and contribution of immunotoxicity in the identification of non-genotoxic carcinogens

免疫的作用和免疫毒性在確定非遺傳毒性致癌物中的貢獻(xiàn)